Patents Assigned to Selecta Biosciences, Inc.
  • Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
    Patent number: 11235057
    Abstract: Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: February 1, 2022
    Assignee: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Aaron P. Griset, Roberto A. Maldonado
  • METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS
    Publication number: 20210308058
    Abstract: This invention relates to synthetic nanocarriers, and related compositions and methods, including wherein the synthetic nanocarrier compositions can be lyophilized, are in a lyophilized form, or a reconstituted composition thereof.
    Type: Application
    Filed: March 11, 2021
    Publication date: October 7, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventor: Lloyd Johnston
  • METHODS AND COMPOSITIONS USING SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT
    Publication number: 20210290601
    Abstract: Provided herein are methods and compositions related to synthetic nanocarriers comprising an immunosuppressant that can be used, for example, for inducing autophagy and/or promoting a tolerogenic phenotype.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 23, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventors: Petr Ilyinskii, Takashi Kei Kishimoto
  • FORMULATIONS AND DOSES OF PEGYLATED URICASE
    Publication number: 20210187081
    Abstract: Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 24, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventors: Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreels
  • METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASES AND DISORDERS
    Publication number: 20210154324
    Abstract: Provided herein are methods and compositions related to compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions for the preventative and therapeutic treatment of liver toxicity, diseases and disorders, such as inflammation-induced, infection-induced or drug-induced hepatotoxicity.
    Type: Application
    Filed: October 21, 2020
    Publication date: May 27, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventors: Petr Ilyinskii, Takashi Kei Kishimoto
  • Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
    Patent number: 10933129
    Abstract: Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: March 2, 2021
    Assignee: Selecta Biosciences, Inc.
    Inventors: David H. Altreuter, Conlin O'Neil, Petr Ilyinskii
  • FORMULATIONS AND DOSES OF PEGYLATED URICASE
    Publication number: 20200399628
    Abstract: Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 24, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreets
  • METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE
    Publication number: 20200390718
    Abstract: Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with synthetic nanocarriers comprising an immunosuppressant and a corticosteroid.
    Type: Application
    Filed: May 28, 2020
    Publication date: December 17, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Petr Ilyinskii
  • NANOCARRIERS POSSESSING COMPONENTS WITH DIFFERENT RATES OF RELEASE
    Publication number: 20200390881
    Abstract: This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise immunomodulatory agents and antigens that are differentially released from the synthetic nanocarriers.
    Type: Application
    Filed: January 27, 2020
    Publication date: December 17, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Grayson B. Lipford, Charles Zepp, Yun Gao, Mark J. Keegan, Sam Baldwin, Fen-ni Fu, Lloyd Johnston
  • METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS
    Publication number: 20200360453
    Abstract: Provided herein are methods and related compositions for administering viral vectors with synthetic nanocarriers comprising an immunosuppressant to subjects. Such subjects may be subjects with pre-existing immunity against a viral antigen of the viral vector.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 19, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Petr Ilyinskii
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN
    Publication number: 20200360350
    Abstract: This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
    Type: Application
    Filed: April 24, 2020
    Publication date: November 19, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
    Patent number: 10668053
    Abstract: This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 2, 2020
    Assignee: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSE
    Publication number: 20200113874
    Abstract: Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
    Type: Application
    Filed: August 26, 2019
    Publication date: April 16, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS
    Publication number: 20200101154
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion).
    Type: Application
    Filed: August 8, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS
    Publication number: 20200101155
    Abstract: Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.
    Type: Application
    Filed: September 4, 2019
    Publication date: April 2, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • METHODS PROVIDING A THERAPEUTIC MACROMOLECULE AND SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT LOCALLY AND CONCOMITANTLY TO REDUCE BOTH TYPE 1 AND TYPE IV HYPERSENSITIVITY
    Publication number: 20200078341
    Abstract: Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity.
    Type: Application
    Filed: June 11, 2019
    Publication date: March 12, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Roberto A. Maldonado
  • METHODS COMPRISING DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES
    Publication number: 20200069660
    Abstract: Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses.
    Type: Application
    Filed: June 6, 2019
    Publication date: March 5, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Roberto A. Maldonado, Takashi Kei Kishimoto
  • METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
    Publication number: 20200069659
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Application
    Filed: May 13, 2019
    Publication date: March 5, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS OF MMA CONSTRUCTS AND VECTORS
    Publication number: 20200038463
    Abstract: Provided herein are methods and compositions related to nucleic acids encoding methylmalonyl-CoA mutase (MUT) as well as related vectors, such as AAV vectors and Anc80 vectors. Also, provided are methods for administering viral vectors that comprise a sequence that encodes an enzyme associated with an organic acidemia and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.
    Type: Application
    Filed: July 16, 2019
    Publication date: February 6, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Peter Keller, Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS OF OTC CONSTRUCTS AND VECTORS
    Publication number: 20200038462
    Abstract: Provided herein are methods and compositions related to nucleic acids encoding ornithine transcarbamylase (OTC), such as nucleic acids comprising an OTC codon-optimized sequence, as well as related vectors, such as AAV vectors. Also, provided are methods for administering AAV vectors that comprise a sequence that encodes an enzyme associated with an urea cycle disorder and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.
    Type: Application
    Filed: July 16, 2019
    Publication date: February 6, 2020
    Applicant: Selecta Biosciences, Inc.
    Inventors: Peter Keller, Takashi Kei Kishimoto, Andres Muro, Giulia De Sabbata